Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise program shows promise for controlling blood pressure in hypertensive patients

NCT ID NCT03923907

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special exercise program could help people with high blood pressure, especially those whose blood pressure doesn't drop enough during sleep (a condition linked to higher heart risks). 198 Chinese adults who did little exercise were split into two groups: one received the exercise program plus usual care, the other just usual care. The goal was to see if exercise could improve blood pressure patterns and overall control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

198 people

The number who actually took part.

Started

Sep 2021

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * SBP non-dippers * self-reported exercise intensity and duration less than the World Health Organization recommendation, which is exercise of moderate intensity less than 150minutes/week OR exercise of vigorous intensity of less than 75 minutes/week * Used any mobile apps on their phone (because the intervention involve use of apps to monitor and remind regular exercise) Exclusion Criteria * Patients with diagnosed chronic obstructive lung disease and recent stroke (within last 12 months) because other evidence-proven and well-structured programmes are implemented for these patients in the hospital authority in Hong Kong * Occupational drivers - because they need to hold their arm still during ABPM and this may be hazardous for drivers * night-time workers * diagnosed Obstructive Sleep Apnea * Patients on anti-coagulants - because ABPM may induce bruises * Patients on 3 or more medications for hypertension (on maximum tolerable doses) - these patients may have secondary HT and represent a different spectrum of organic diseases * Patients with SBP \>180mmHg or DBP \>110mmHg - drug titration is not allowed during the 12-week program and these patients need early drug treatment * Patient with DM - these patients will be arranged to have another EIM program especially designed for their DM. * Patients with active spinal cord compression or spinal radiculopathy because they may not be suitable to join some exercise * patients with atrial fibrillation are excluded because these patients have increased BP variability and may have different dipping behaviour * patients with metallic implants or pacemakers are excluded as they are not suitable for MRI * To maximize safety of patients, patients who are relatively contraindicated according to AHA will also be excluded * acute myocardial infarction in last 6 months * ongoing angina * uncontrolled cardiac arrhythmia * acute diseases including known active endocarditis/acute pulmonary embolism, pulmonary infarction, deep vein thrombosis, acute aortic dissection, acute myocarditis * known aortic stenosis * known heart failure * known obstructive left main coronary artery stenosis * uncontrolled ventricular rates * complete heart block * known hypertrophic obstructive cardiomyopathy * mental impairment that limit co-operation * resting blood pressure with systolic blood pressure \>180mmHg or diastolic blood pressure \>110mmHg * known anemia with hemoglobin level less than 11gm/dL * known uncorrected electrolyte imbalance, and * known uncontrolled hyperthyroidism.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Lek Yuen Clinic

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.